Dr. Michael Burgess is a recognized senior leader in the pharmaceutical industry with nearly 30 years of drug research and development experience.
Most recently he was both the interim CMO and an executive director at Turnstone Biologics. He was Head of R&D at both Springworks Therapeutics and Turnstone Biologics. Before joining Turnstone, he led strategy and execution of translational medicine, early-stage clinical trials and clinical pharmacology across all therapeutic areas, including oncology at Bristol-Myers Squibb. Prior to this, he was at Roche Pharmaceuticals, where he held several senior leadership positions, including acting global head of Roche Pharma Research and Early Development (pRED), and Senior Vice President and Global Head of Oncology Research and Early Development. Before joining Roche, Mike spent 7 years at Lilly working on early stage oncology trials. Mike has also served as a member of the board of Synlogic Therapeutics and is a member of the portfolio committee for the Experimental Drug Development Center in Singapore.
Mike received his medical degree (M.B., Ch.B.) and a Ph.D. in molecular biology from the University of Bristol, UK and spent 10 years as a practicing physician in pediatrics and pediatric oncology
